Grifols

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Subsidiary, Public

Established: 1940-01-01

Employees: 23.7K

Market Cap: $6.8B

Website: http://www.grifols.com

Introduction: Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Clinical Trials

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)

Phase 4

Completed

Conditions: Anti-Hepatitis A Antibody Levels in Heathy Subjects

Interventions: Biological: Immune Globulin (Human)

First Posted Date: 2017-11-24

Last Posted Date: 2019-07-30

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 28

Registration Number: NCT03351933

Locations: 🇺🇸
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States

Alphanate in Immune Tolerance Induction Therapy

Phase 2

Terminated

Conditions: Hemophilia A, Congenital

Interventions: Biological: Alphanate

First Posted Date: 2017-03-29

Last Posted Date: 2021-11-23

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 2

Registration Number: NCT03095287

Locations: 🇺🇸
Newark Beth Israel Medical Center & Children's Hospital of New Jersey, Newark, New Jersey, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇮🇳
Lokmanya Tilak Municipal Medical College & General Hospital, Mumbai, Maharashtra, India

and more 17 locations

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Biological: Albutein 5%
Procedure: Plasma Exchange

First Posted Date: 2016-08-19

Last Posted Date: 2021-05-05

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 12

Registration Number: NCT02872142

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

Phase 1

Completed

Conditions: Alpha1-Antitrypsin Deficiency

Interventions: Biological: Alpha-1 MP

First Posted Date: 2016-08-17

Last Posted Date: 2022-03-31

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 4

Registration Number: NCT02870348

Locations: 🇯🇵
Hiroskai University Hospital, Aomori, Japan
🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇯🇵
Juntendo University Hospital, Tokyo, Japan

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

Phase 1

Completed

Conditions: Alpha1-Antitrypsin Deficiency

Interventions: Biological: Alpha-1 MP

First Posted Date: 2016-08-17

Last Posted Date: 2021-10-28

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 4

Registration Number: NCT02870309

Locations: 🇯🇵
Juntendo University Hospital, Tokyo, Japan
🇯🇵
Hokkaido University Hospital, Sapporo, Japan

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Phase 3

Completed

Conditions: Primary Immunodeficiency

Interventions: Biological: IGSC 20%

First Posted Date: 2016-06-21

Last Posted Date: 2020-06-16

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 61

Registration Number: NCT02806986

Locations: 🇫🇷
CHU de Montpellier, Montpellier, France
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇨🇿
University Hospital, Hradec Kralove, Czechia

and more 20 locations

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

Phase 3

Conditions: Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

Interventions: Biological: Alpha-1 MP

First Posted Date: 2016-06-13

Last Posted Date: 2024-08-07

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 290

Registration Number: NCT02796937

Locations: 🇺🇸
Accellacare, Wilmington, North Carolina, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇦🇺
Royal Adelaide Hospital, Adelaide, Australia

and more 24 locations

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Phase 3

Completed

Conditions: Primary Immunodeficiency

Interventions: Biological: IGIV-C 10%
Biological: IGSC 20%

First Posted Date: 2015-11-13

Last Posted Date: 2019-10-04

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 53

Registration Number: NCT02604810

Locations: 🇺🇸
Allergy Associates of The Palm Beaches, PA, North Palm Beach, Florida, United States
🇺🇸
University of South Florida, Saint Petersburg, Florida, United States
🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada

and more 22 locations

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Phase 2

Completed

Conditions: Myasthenia Gravis

Interventions: Drug: Placebo
Drug: IGIV-C

First Posted Date: 2015-06-17

Last Posted Date: 2020-03-30

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 60

Registration Number: NCT02473965

Locations: 🇺🇸
University of California-Irvine, Orange, California, United States
🇺🇸
University of Florida at Shands Jacksonville, Jacksonville, Florida, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 36 locations

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Phase 2

Completed

Conditions: Myasthenia Gravis, Generalized

Interventions: Drug: IGIV-C
Drug: Placebo

First Posted Date: 2015-06-17

Last Posted Date: 2019-03-05

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 62

Registration Number: NCT02473952

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 37 locations

Home Terms & Conditions Privacy Policy